SPRINT — Sprint Bioscience AB Balance Sheet
0.000.00%
- SEK90.63m
- SEK50.74m
- SEK50.49m
- 62
- 70
- 55
- 69
Annual balance sheet for Sprint Bioscience AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Short Term Investments | 8.38 | 27.1 | 70.6 | 29.5 | 49.9 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 6.82 | 3.28 | 5.29 | 5.39 | 7.94 |
Prepaid Expenses | |||||
Total Current Assets | 17.4 | 32.3 | 75.9 | 34.9 | 57.9 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1.57 | 0.872 | 2.99 | 2.37 | 4.38 |
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 19.2 | 33.4 | 79.1 | 37.4 | 62.4 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 8.23 | 24.3 | 8.68 | 9.23 | 34.6 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Liabilities | 8.23 | 24.3 | 8.68 | 9.23 | 34.6 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 11 | 9.14 | 70.5 | 28.2 | 27.8 |
Total Liabilities & Shareholders' Equity | 19.2 | 33.4 | 79.1 | 37.4 | 62.4 |
Total Common Shares Outstanding |